BACKGROUND: Case-control studies often analyze risk factors for antibiotic resistance. Recently published articles have illustrated that randomly selected control-patients may be preferable to those with the susceptible phenotype of the organism. A possible methodologic problem with randomly selected control-patients is potential bias due to control group misclassification. This occurs if some control-patients did not have clinical cultures performed and thus might have been unidentified case-patients. If this bias exists, these studies might be expected to report lower odds ratios (ORs) because control-patients would be more like case-patients. OBJECTIVE: To analyze potential biases that might arise due to control group misclassification and potentially larger selection biases that may be introduced if control-patients are required to have at least one clinical culture. PATIENTS: One hundred twenty case-patients, 770 control-patients in group 1, and 510 control-patients in group 2. METHODS: Two case-control studies. Case-patients had clinical cultures positive for imipenem-resistant Pseudomonas aeruginosa. The first group of control-patients were random. The second group of control-patients were identical to those in group 1 except being required to have at least one clinical culture. RESULTS: Univariate analyses showed higher ORs for case-patients versus control-patients in group 1 (imipenem [OR, 12.5], piperacillin-tazobactam [OR, 3.7], and vancomycin [OR, 4.7]) as compared with case-patients versus control-patients in group 2 (imipenem [OR, 8.0], piperacillin-tazobactam [OR, 2.5], and vancomycin [OR, 3.0]). CONCLUSION: Requiring control-patients to have at least one clinical culture introduces a selection bias likely because it eliminates patients with less severe illness.
BACKGROUND: Case-control studies often analyze risk factors for antibiotic resistance. Recently published articles have illustrated that randomly selected control-patients may be preferable to those with the susceptible phenotype of the organism. A possible methodologic problem with randomly selected control-patients is potential bias due to control group misclassification. This occurs if some control-patients did not have clinical cultures performed and thus might have been unidentified case-patients. If this bias exists, these studies might be expected to report lower odds ratios (ORs) because control-patients would be more like case-patients. OBJECTIVE: To analyze potential biases that might arise due to control group misclassification and potentially larger selection biases that may be introduced if control-patients are required to have at least one clinical culture. PATIENTS: One hundred twenty case-patients, 770 control-patients in group 1, and 510 control-patients in group 2. METHODS: Two case-control studies. Case-patients had clinical cultures positive for imipenem-resistant Pseudomonas aeruginosa. The first group of control-patients were random. The second group of control-patients were identical to those in group 1 except being required to have at least one clinical culture. RESULTS: Univariate analyses showed higher ORs for case-patients versus control-patients in group 1 (imipenem [OR, 12.5], piperacillin-tazobactam [OR, 3.7], and vancomycin [OR, 4.7]) as compared with case-patients versus control-patients in group 2 (imipenem [OR, 8.0], piperacillin-tazobactam [OR, 2.5], and vancomycin [OR, 3.0]). CONCLUSION: Requiring control-patients to have at least one clinical culture introduces a selection bias likely because it eliminates patients with less severe illness.
Authors: Marlieke E A de Kraker; Martin Wolkewitz; Peter G Davey; Walter Koller; Jutta Berger; Jan Nagler; Claudine Icket; Smilja Kalenic; Jasminka Horvatic; Harald Seifert; Achim J Kaasch; Olga Paniara; Athina Argyropoulou; Maria Bompola; Edmond Smyth; Mairead Skally; Annibale Raglio; Uga Dumpis; Agita Melbarde Kelmere; Michael Borg; Deborah Xuereb; Mihaela C Ghita; Michelle Noble; Jana Kolman; Stanko Grabljevec; David Turner; Louise Lansbury; Hajo Grundmann Journal: Antimicrob Agents Chemother Date: 2011-01-10 Impact factor: 5.191
Authors: Thomas P Lodise; Christopher D Miller; Jeffrey Graves; Jon P Furuno; Jessina C McGregor; Ben Lomaestro; Eileen Graffunder; Louise-Anne McNutt Journal: Antimicrob Agents Chemother Date: 2006-12-11 Impact factor: 5.191
Authors: Dror Marchaim; Teena Chopra; Ashish Bhargava; Christopher Bogan; Sorabh Dhar; Kayoko Hayakawa; Jason M Pogue; Suchitha Bheemreddy; Christopher Blunden; Maryann Shango; Jessie Swan; Paul R Lephart; Federico Perez; Robert A Bonomo; Keith S Kaye Journal: Infect Control Hosp Epidemiol Date: 2012-06-11 Impact factor: 3.254
Authors: Michael D Dallman; Xinggang Liu; Anthony D Harris; John R Hess; Bennett B Edelman; David J Murphy; Giora Netzer Journal: Pediatr Crit Care Med Date: 2013-11 Impact factor: 3.624
Authors: Kevin S Akers; Katrin Mende; Kristelle A Cheatle; Wendy C Zera; Xin Yu; Miriam L Beckius; Deepak Aggarwal; Ping Li; Carlos J Sanchez; Joseph C Wenke; Amy C Weintrob; David R Tribble; Clinton K Murray Journal: BMC Infect Dis Date: 2014-04-08 Impact factor: 3.090